complement therapeutics
innovation breakthrough
Teamwork motivation
Discovery for patients

Welcome to InflaRx!

InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.

InflaRx focuses on the development of first-in-class monoclonal antibodies targeting activation products of the complement system for application in life threatening inflammatory diseases and other inflammatory diseases

Our lead drug candidate, IFX-1, is currently in clinical phase II development in different acute inflammatory indications.


New Pipeline Addition IFX-2

IFX-2 as highly humanized
monoclonal anti-complement

Competence in Intensive Care

Clinical Trial Hub Jena
Preventive approaches
in intensive care
InflaRx GmbH
Winzerlaer Str. 2
07745 Jena, Germany
+049 3641-508180 EMail: